EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients

Jinyan Xiao iD, Yujie Liu, Yifan Shen, Jiaqi Li, Ying Wang iD, Suning Chen iD, Xiaowen Tang iD, Lin Yang, Biqi Zhou, Yang Xu, Depei Wu

Hematological Oncology · 2025-05 · 43 (3)

DOI: 10.1002/hon.70081 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 14.04.2025. Verfasst von Jinyan Xiao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suz…. Hauptthemen laut MEDLINE: Immunotherapy, Adoptive, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Receptors, Chimeric Antigen, Antigens, CD7. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: the Natural Science Foundation of China, National Key Research and Development Program of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Relapse and refractory T‐cell acute lymphoblastic leukemia and lymphoblastic lymphoma (R/R T‐ALL/LBL) patients have poor outcomes. Chimeric antigen receptor (CAR)‐T‐cell therapy for T‐ALL/LBL has shown encouraging results in the early stages of clinical trials. Here, we retrospectively analyzed the outcomes of 12 patients with R/R T‐ALL/LBL who received CD7 CAR‐T cell therapy. Eleven patients received autologous CAR‐T cells, while one patient received allogeneic CAR‐T cells. On Day 28 post‐infusion, 67% (8/12) of patients achieved an overall response (ORR). At a median follow‐up of 134 (14–925) days, the median overall survival (OS) was 134 days, and the progression‐free survival (PFS) was 81 days. Among the 8 patients who achieved remission after CD7 CAR‐T cell infusion, 5 patients received consolidation allogeneic hematopoietic stem cell transplantation (allo‐HSCT). Compared with 3 patients who did not undergo consolidation allo‐HSCT, patients with allo‐HSCT as consolidation showed a trend toward better OS (allo‐HSCT vs. control: 6‐month OS, 60% vs. 33.3%, p = 0.073) and better PFS (allo‐HSCT vs. control: 6‐month PFS, 60% vs. 0%, p = 0.022). Cytokine release syndrome (CRS) occurred in all patients (grade 1–2 in 67% of patients, grade 3 in 33% of patients), and one patient experienced neurotoxicity. CD7 CAR‐T cell therapy is a promising option for R/R T‐ALL/LBL patients with manageable adverse events. Moreover, CD7 CAR‐T cell infusion followed by consolidation allo‐HSCT in R/R T‐ALL/LBL patients might play an important role in prolonging remission duration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Immunotherapy, AdoptivePrecursor T-Cell Lymphoblastic Leukemia-LymphomaReceptors, Chimeric AntigenAntigens, CD7Precursor Cell Lymphoblastic Leukemia-LymphomaHumansMaleFemaleAdultRetrospective StudiesMiddle AgedYoung AdultAdolescentHematopoietic Stem Cell TransplantationSurvival RateTreatment OutcomeChild

Stichwörter der Autor:innen

CD7allogeneic hematopoietic stem cell transplantationchimeric antigen receptor T cell therapyleukemialymphoma

Substanzen

Receptors, Chimeric AntigenAntigens, CD7

Autor:innen und Institutionen

  • Jiangsu Institute of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China.
  • Cyrus Tang Medical Institute, Collaborative Innovation Center of Hematology, State Key Laboratory of Radiation Medicine and Protection, Soochow University, Suzhou, China.
  • PersonGen BioTherapeutics (Suzhou) Co. Ltd., Suzhou, China.

ORCID-Profile: Jinyan Xiao, Ying Wang, Suning Chen, Xiaowen Tang

Förderung

  • the Natural Science Foundation of China
  • National Key Research and Development Program of China

Zitieren

APA

Xiao, J., Liu, Y., Shen, Y., Li, J., Wang, Y., Chen, S., Tang, X., Yang, L., Zhou, B., Xu, Y., & Wu, D. (2025). Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients. Hematological Oncology, 43(3). https://doi.org/10.1002/hon.70081

Vancouver

Xiao J, Liu Y, Shen Y, Li J, Wang Y, Chen S, et al. Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients. Hematological Oncology. 2025;43(3). doi:10.1002/hon.70081

BibTeX
@article{Xiao2025,
  author = {Xiao, Jinyan and Liu, Yujie and Shen, Yifan and Li, Jiaqi and Wang, Ying and Chen, Suning and Tang, Xiaowen and Yang, Lin and Zhou, Biqi and Xu, Yang and Wu, Depei},
  title = {Clinical Outcomes of CD7 CAR‐T Cell Therapy in Relapsed or Refractory T‐Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Patients},
  journal = {Hematological Oncology},
  year = {2025},
  volume = {43},
  number = {3},
  doi = {10.1002/hon.70081}
}
Kostenlos starten →